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Protein kinase C θ (PKC θ) is a serine/
threonine kinase that is now firmly estab-
lished as a central component in T cell acti-
vation, proliferation, differentiation, and 
apoptosis (Hayashi and Altman, 2007). 
Since it was first discovered that PKC θ 
re-localizes to the immunological syn-
apse (IS) in conventional effector T cells 
following T cell stimulation, many roles 
have now been defined for this kinase in 
these cells such as (a) activation of NF-κB, 
AP-1, and NFAT transcription factors that 
control the synthesis of pro-inflammatory 
cytokines and the anti-apoptotic molecule 
Bcl-x
L
 (Hayashi and Altman, 2007), (b) 
regulation of IS dynamics (Sims et al., 
2007), (c) up-regulation and clustering of 
the integrin LFA-1 on the T cell surface 
(Tan et al., 2006; Letschka et al., 2008) – 
thus facilitating stable adhesion between 
T cells and antigen-presenting cells (APC) 
and/or migration into inflamed tissues, 
(d) re-orientation of the microtubule-
organizing center toward the APC (Quann 
et al., 2011), and (e) fine tuning of T cell 
activation by regulating the intracellular 
localization, degradation, and internali-
zation of key signaling molecules (Nika 
et al., 2006; von Essen et al., 2006; Gruber 
et al., 2009). A new function for PKC θ 
has also recently been revealed with the 
finding that this kinase regulates an induc-
ible gene expression program in T cells by 
associating with chromatin in the nucleus 
(Sutcliffe et al., 2011).
A host of studies have now convincingly 
demonstrated that targeting PKC θ could 
be a viable therapeutic strategy to block 
the T cell inflammatory response in auto-
immunity, allergy, and allograft rejection 
(Marsland and Kopf, 2008; Zanin-Zhorov 
et al., 2011; Altman and Kong, 2012). For 
example, PKC θ-deficient mice (PKC θ−/−) 
have reduced incidence and severity of 
Th2 and Th17-mediated inflammatory 
disorders, including asthma, inflammatory 
bowel disease, multiple sclerosis, arthritis, 
and allograft rejection in comparison 
to their wild-type littermates (PKC θ+/+; 
Marsland and Kopf, 2008; Zanin-Zhorov 
et al., 2011; Altman and Kong, 2012). 
Intriguingly, PKCθ−/− mice are still capa-
ble of mounting relatively normal Th1 and 
CD8+ T cell-mediated immune responses 
to infectious viruses (Marsland and Kopf, 
2008; Zanin-Zhorov et al., 2011; Altman 
and Kong, 2012). Secondly, the recent find-
ing that inhibition of PKC θ increases the 
suppressive activity of regulatory T cells 
(Zanin-Zhorov et al., 2010) suggests that 
therapeutic strategies designed to inhibit 
this kinase may hold great promise in 
diverting the pro/anti-inflammatory bal-
ance toward a reduction in inflammation 
in T cell autoimmunity and allergy, whilst 
at the same time maintaining immunity 
to viral pathogens. Lastly, that PKC θ has 
a restricted tissue expression profile and is 
highly expressed in T cells suggests that tar-
geting this molecule with specific inhibi-
tors should have minimal effects in other 
cells and tissues (Hayashi and Altman, 
2007; Altman and Kong, 2012). In spite of 
all this promising data however, a number 
of studies have demonstrated that target-
ing PKC θ could potentially have some 
undesired effects. For example, it has been 
reported that CD8+ T cells from PKC θ−/− 
mice have a survival defect following acti-
vation (Barouch-Bentov et al., 2005; Saibil 
et al., 2007; Kingeter and Schaefer, 2008). 
In addition, it has been reported that PKC 
θ−/− mice have an impaired anti-leukemic 
response (Garaude et al., 2008), which 
likely results from reduced tumor surveil-
lance in vivo. It is important therefore that 
these issues are addressed in respect of any 
PKC θ-targeting strategies that are devel-
oped in the future.
Although much has been learned about 
PKC θ in T cells, considerable gaps still exist 
in our knowledge as to how this kinase is 
regulated, including the upstream signals 
and interacting partners that control its 
intracellular localization and catalytic 
activation at various locations in the cell. 
Furthermore, although a plethora of sub-
strates that are phosphorylated by PKC θ 
in vitro have now been characterized (Nika 
et al., 2006; Hayashi and Altman, 2007; 
Letschka et al., 2008), whether any of these 
are bona fide substrates in vivo remains to 
be addressed. Like many other kinases, 
PKC θ is also regulated by phosphorylation 
on a host of serine, threonine, and tyros-
ine residues that influence its activity and 
intracellular localization. Six phosphoryla-
tion sites have been mapped on PKC θ in T 
cells to date. Some of these sites appear to 
be phosphorylated by unrelated upstream 
kinases, while other sites are regulated 
via auto-phosphorylation. Three of these 
phosphorylation sites are highly conserved 
on most other PKC isoforms, which sug-
gests that they may regulate aspects that are 
central to all isoforms, such as stability. In 
contrast, PKC θ contains three phospho-
rylation sites that appear to be unique to 
this isoform.1 Therefore PKC θ may exe-
cute distinct functions and/or be regulated 
differently in T cells (Freeley et al., 2011). 
In this issue of Frontiers in T Cell Biology, 
Wang et al. (2012) summarize the regula-
tion of PKC θ by phosphorylation during T 
cell signaling. Understanding the pathways 
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1Some of these three residues on PKC θ may also be 
found in other PKC isoforms, but their phosphoryla-
tion on other PKCs has not been described.
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that regulate PKC θ in T cells may provide 
additional therapeutic targets for the treat-
ment of inflammatory diseases.
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